Literature DB >> 394875

Antibodies as specific carriers for chemotherapeutic agents.

F H Lee, K M Hwang.   

Abstract

Mesh：

Substances：

Year:  1979        PMID： 394875     DOI： 10.1007/bf00254415

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  46 in total

1.  Immunochemotherapy of human malignant melanoma with chlorambucil-carrying antibody.

Authors:  T Ghose; S T Norvell; A Guclu; A S Macdonald
Journal:  Eur J Cancer       Date:  1975-05       Impact factor: 9.162

2.  Localization in vivo of radio-iodinated anti-rat-fibrin antibodies and radio-iodinated rat fibrinogen in the Murphy rat lymphosarcoma and in other transplantable rat tumors.

Authors:  E D DAY; J A PLANINSEK; D PRESSMAN
Journal:  J Natl Cancer Inst       Date:  1959-02       Impact factor: 13.506

3.  Melanotropin-daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells.

Authors:  J M Varga; N Asato; S Lande; A B Lerner
Journal:  Nature       Date:  1977-05-05       Impact factor: 49.962

4.  Effective antitumour conjugates of alkylating drug and antibody using dextran as the intermediate carrier.

Authors:  G F Rowland
Journal:  Eur J Cancer       Date:  1977-06       Impact factor: 9.162

5.  In vivo and in vitro effects of tumour specific antibodies with chlorambucil.

Authors:  D A Davies; G J O'Neill
Journal:  Br J Cancer Suppl       Date:  1973-08

Review 6.  Principles and methods for the preparation of drug protein conjugates for immunological studies.

Authors:  B F Erlanger
Journal:  Pharmacol Rev       Date:  1973-06       Impact factor: 25.468

7.  Augmentation of cytotoxic drug action by antibodies directed at cell surface.

Authors:  R D Rubens; R Dulbecco
Journal:  Nature       Date:  1974-03-01       Impact factor: 49.962

8.  An alkylating agent-globulin conjugate with both alkylating and antibody activity.

Authors:  J H Lindford; G Froese; I Berczi; L G Israels
Journal:  J Natl Cancer Inst       Date:  1974-05       Impact factor: 13.506

9.  Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas.

Authors:  I Hellström; K E Hellström
Journal:  Int J Cancer       Date:  1970-03-15       Impact factor: 7.396

10.  Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates.

Authors:  S Burstein; R Knapp
Journal:  J Med Chem       Date:  1977-07       Impact factor: 7.446
View more
  5 in total

Review 1.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Sensitization to low dose 5-fluorouracil. Subsequent enhancement of its systemic antitumor effect in the rat.

Authors:  R E Falk; M Hardy; L Makowka; J Teodorczyk-Injeyan; J A Falk
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

3.  A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro.

Authors:  J R Johnson; C H Ford; C E Newman; C S Woodhouse; G F Rowland; R G Simmonds
Journal:  Br J Cancer       Date:  1981-09       Impact factor: 7.640

4.  The effect of an anti-membrane antibody-methotrexate conjugate on the human prostatic tumour line PC3.

Authors:  A J Rowland; M E Harper; D W Wilson; K Griffiths
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

5.  Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer.

Authors:  C H Ford; C E Newman; J R Johnson; C S Woodhouse; T A Reeder; G F Rowland; R G Simmonds
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.